Form 4: Arcus Biosciences Director Antoni Ribas Reports Stock and Option Grants

Director Antoni Ribas reported the acquisition of restricted stock units and stock options in Arcus Biosciences.

Summary

• On June 6, 2024, Antoni Ribas, a director of Arcus Biosciences, acquired 8,400 shares of common stock through restricted stock units (RSUs) and was granted an option to purchase 24,000 shares.
• The RSUs vest fully on the earlier of June 6, 2025, or the next annual meeting of stockholders, and will fully vest upon a change in control of the company.
• The stock option, with an exercise price of $15.90, also vests fully on the earlier of June 6, 2025, or the next annual meeting of stockholders, and will become fully vested and exercisable upon a change in control.
• Ribas also indirectly owns 8,553 shares through a trust.
• Following these transactions, Ribas directly owns 30,350 shares of common stock.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices, indicating a stable and incentivized leadership structure. The vesting conditions suggest a focus on long-term value creation, which is generally viewed positively.

Positives

• The grant of RSUs and stock options to a director aligns their interests with those of the shareholders.
• The vesting conditions tied to the annual meeting and change in control provide incentives for long-term value creation and strategic decision-making.

Future Outlook

The vesting of the RSUs and stock options is contingent upon future events, including the annual meeting of stockholders and potential change in control of the company.

Industry Context

Stock grants and options are common forms of executive compensation in the biotechnology industry, aligning management's interests with shareholder value creation. These grants are often structured with vesting schedules tied to performance or time-based milestones.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors and executives in biotech companies like Arcus Biosciences.
• Companies such as Gilead Sciences, Amgen, and Regeneron Pharmaceuticals also utilize stock options and restricted stock units to incentivize their leadership teams.
• The vesting schedules, typically spanning one to four years, are designed to retain key personnel and align their interests with long-term shareholder value.
• The size of the grant is comparable to grants given to directors at similar stage companies.

Stakeholder Impact

• The stock and option grants align the director's interests with those of the shareholders, incentivizing value creation.
• Employees may be indirectly impacted by the director's incentivization to improve company performance.

Key Dates